Shojaku Hideo, Watanabe Yukio, Mineta Hiroyuki, Aoki Mitsuhiro, Tsubota Masahito, Watanabe Kazumichi, Goto Fumiyuki, Shigeno Koichiro
Department of Otolaryngology, University of Toyama, Japan.
Acta Otolaryngol. 2011 Mar;131(3):277-83. doi: 10.3109/00016489.2010.526142.
The Meniett device is a minimally invasive and safe treatment that may be used to provide longer-term reduction of vestibular symptoms in patients with delayed endolymphatic hydrops (DEH) as well as those with Meniere's disease (MD).
The effects of the Meniett device were evaluated in patients with a diagnosis of definite MD or DEH according to the 1995 AAO-HNS criteria.
Twenty-nine ears of 28 patients with MD and 5 ears of 5 patients with DEH (ipsilateral type 4, contralateral type 1) were treated with the Meniett device by the Middle Ear Pressure Treatment Research Group of Japan. All of the patients had failed to respond to medical treatment including diuretics before the pressure treatment.
Sixteen (57%) patients with MD and all five (100%) patients with DEH remained entirely free from vertigo spells; nine (32%) patients with MD responded with a significant decrease in the frequency of vertigo spells. In regard to hearing, 25 ears (74%: MD, n = 21; ipsilateral DEH, n = 4) had stable hearing levels; only 4 ears (12%: MD, n = 3; contralateral DEH, n = 1) showed a significant hearing improvement. No complications were attributable to the Meniett device.
梅涅特装置是一种微创且安全的治疗方法，可用于长期减轻迟发性内淋巴积水（DEH）患者以及梅尼埃病（MD）患者的前庭症状。
根据1995年美国耳鼻咽喉头颈外科学会（AAO-HNS）标准，评估梅涅特装置对确诊为MD或DEH患者的疗效。
日本中耳压力治疗研究组使用梅涅特装置对28例MD患者的29只耳和5例DEH患者（同侧4型，对侧1型）的5只耳进行治疗。所有患者在压力治疗前对包括利尿剂在内的药物治疗均无反应。
16例（57%）MD患者和所有5例（100%）DEH患者完全没有眩晕发作；9例（32%）MD患者眩晕发作频率显著降低。在听力方面，25只耳（74%：MD，n = 21；同侧DEH，n = 4）听力水平稳定；只有4只耳（12%：MD，n = 3；对侧DEH，n = 1）听力有显著改善。没有并发症可归因于梅涅特装置。
